HBI-3000

DRUG3 trials

Sponsors

HUYABIO International, LLC.

Conditions

Atrial FibrillationDrug-drug Interaction

Phase 1

A Phase 1 Study of HBI-3000

CompletedNCT03397641

HUYABIO International, LLC.Atrial Fibrillation

Start: 2017-10-17End: 2018-07-10Updated: 2018-08-29

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

CompletedNCT04650542

HUYABIO International, LLC.Drug-drug Interaction

Start: 2021-02-21End: 2021-08-13Updated: 2022-07-15

Phase 2

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Active, not recruitingNCT04680026

HUYABIO International, LLC.Atrial Fibrillation

Start: 2021-06-01End: 2025-12-31Target: 150Updated: 2025-12-02

Related Papers

Abstract 4136839: HBI-3000: Pharmacological Conversion of Atrial Fibrillation With Unique Defense Against Excessive QT Interval Prolongation

Circulation2024-11-12